NR1H4 and atherosclerosis: Because development of therapeutic interventions to effectively counteract the complications of HIV PIs based therapy is especially urgent, we have investigated whether FXR agonism protects against dyslipidemia and vascular injury induced by ritonavir, a widely used HIV-PIs, in rodent models of dyslipidemia-driven atherosclerosis.